Alkem Laboratories Ltd

In Q1 FY2027, Alkem Laboratories Limited reported revenue of INR3,740 crores, up 11% YoY, with India sales growing 10.3% and international sales rising 16%. EBITDA margin was 20.5%, up 3.7% YoY, while R&D expenses accounted for 4% of total revenue. Net profit declined 21.7% due to taxation factors. The company outperformed the Indian pharmaceutical market (IPM) by 100 basis points, with the chronic segment growing 17.9% versus IPM's 15.4%. Key therapeutic areas like anti-infectives, gastro, and vitamins showed strong growth. The U.S. market received 5 ANDA approvals, including one tentative, and the Daman facility achieved OAI status. However, the Trade Generics segment faced growth challenges due to competitive pressures and stricter credit policies, with growth flattening in April-June. The CDMO business, including U.S. operations, incurred INR60 crores in quarterly expenses, with breakeven expected in 4-5 quarters. Management guided toward mid to high single-digit U.S. growth for FY2027, supported by currency factors. Branded formulations and biosimilars contributed positively, with 7 biosimilars launched in India generating INR150 crores annually. The Occlutech acquisition is expected to reach breakeven in 8.5 months, with margin improvements anticipated over 3-4 years. Management emphasized disciplined capital allocation and operational efficiency amid external challenges.

The summary presents factual results, challenges, and guidance without overtly positive or negative language.